PriceTargets.com logo

Harrow - HROW Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $71.43
  • Forecasted Upside: 52.72%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$46.77 As of 12/4/2025 05:00 PM ET
▲ +2.25 (5.05%)

This chart shows the closing price for HROW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harrow Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HROW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HROW

Analyst Price Target is $71.43
▲ +52.72% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Harrow in the last 3 months. The average price target is $71.43, with a high forecast of $94.00 and a low forecast of $63.00. The average price target represents a 52.72% upside from the last price of $46.77.

This chart shows the closing price for HROW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 investment analysts is to moderate buy stock in Harrow. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/12/2025LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$64.00 ➝ $66.00
11/12/2025HC WainwrightBoost TargetBuy ➝ Buy$64.00 ➝ $69.00
11/11/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$94.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/1/2025B. RileyReiterated RatingBuy ➝ Buy$70.00 ➝ $74.00
9/29/2025Lake Street CapitalBoost TargetBuy ➝ Buy$42.00 ➝ $70.00
9/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$64.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/24/2025BTIG ResearchReiterated RatingBuy ➝ Buy$63.00
9/23/2025B. RileyBoost TargetBuy ➝ Buy$65.00 ➝ $70.00
9/23/2025Craig HallumBoost TargetBuy ➝ Buy$54.00 ➝ $64.00
9/12/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/14/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
8/14/2025BTIG ResearchBoost TargetBuy ➝ Buy$62.00 ➝ $63.00
8/13/2025HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $64.00
7/11/2025Cantor FitzgeraldInitiated CoverageOverweight$76.00
6/12/2025BTIG ResearchInitiated CoverageBuy$62.00
6/10/2025William BlairInitiated CoverageOutperform
5/12/2025HC WainwrightBoost TargetBuy ➝ Buy$57.00 ➝ $60.00
4/1/2025B. RileyLower TargetBuy ➝ Buy$69.00 ➝ $65.00
3/31/2025HC WainwrightReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
3/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
2/6/2025HC WainwrightInitiated CoverageBuy$57.00
12/4/2024B. RileyLower TargetBuy$73.00 ➝ $69.00
10/4/2024Lake Street CapitalBoost TargetBuy ➝ Buy$45.00 ➝ $55.00
10/4/2024Craig HallumBoost TargetBuy ➝ Buy$45.00 ➝ $65.00
8/29/2024B. RileyReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
8/9/2024Craig HallumBoost TargetBuy ➝ Buy$30.00 ➝ $45.00
8/9/2024B. RileyBoost TargetBuy ➝ Buy$29.00 ➝ $50.00
6/21/2024Craig HallumBoost TargetBuy ➝ Buy$26.00 ➝ $30.00
6/3/2024Lake Street CapitalBoost TargetBuy ➝ Buy$20.00 ➝ $25.00
5/15/2024Craig HallumBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
5/15/2024B. RileyReiterated RatingBuy ➝ Buy$26.00 ➝ $29.00
4/11/2024Craig HallumInitiated CoverageBuy$24.00
3/22/2024B. RileyLower TargetBuy ➝ Buy$30.00 ➝ $26.00
8/10/2023LADENBURG THALM/SH SHBoost Target$33.70 ➝ $34.40
7/20/2023B. RileyBoost TargetBuy$42.00 ➝ $45.00
5/12/2023LADENBURG THALM/SH SHBoost Target$27.20 ➝ $32.40
5/4/2023B. RileyReiterated RatingBuy
4/17/2023Lake Street CapitalBoost TargetBuy$24.00 ➝ $37.00
1/24/2023Lake Street CapitalBoost Target$17.00 ➝ $24.00
1/5/2023B. RileyBoost Target$17.00 ➝ $22.00
9/8/2022B. RileyInitiated CoverageBuy$17.00
5/20/2022B. RileyBoost TargetBuy$17.00 ➝ $20.00
10/14/2021B. RileyInitiated CoverageBuy$16.00
9/23/2021AegisInitiated CoverageBuy$15.00
7/2/2021LADENBURG THALM/SH SHInitiated CoverageBuy$14.25
5/12/2021B. RileyBoost TargetBuy$14.00 ➝ $15.00
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$12.00 ➝ $14.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 21 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 8 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 9 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 18 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 19 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 10 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 18 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 18 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Harrow logo
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $46.77
Low: $43.54
High: $46.90

50 Day Range

MA: $40.15
Low: $33.93
High: $48.40

52 Week Range

Now: $46.77
Low: $20.85
High: $50.72

Volume

680,424 shs

Average Volume

679,880 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Harrow?

The following Wall Street analysts have issued reports on Harrow in the last twelve months: B. Riley, BTIG Research, Cantor Fitzgerald, Craig Hallum, HC Wainwright, LADENBURG THALM/SH SH, Lake Street Capital, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for HROW.

What is the current price target for Harrow?

0 Wall Street analysts have set twelve-month price targets for Harrow in the last year. Their average twelve-month price target is $71.43, suggesting a possible upside of 52.7%. Cantor Fitzgerald has the highest price target set, predicting HROW will reach $94.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $63.00 for Harrow in the next year.
View the latest price targets for HROW.

What is the current consensus analyst rating for Harrow?

Harrow currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HROW.

What other companies compete with Harrow?

Other companies that are similar to Harrow include Cogent Biosciences, Protagonist Therapeutics, Legend Biotech, CRISPR Therapeutics and TG Therapeutics. Learn More about companies similar to Harrow.

How do I contact Harrow's investor relations team?

Harrow's physical mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company's listed phone number is (615) 733-4730 and its investor relations email address is [email protected]. The official website for Harrow is www.harrowinc.com. Learn More about contacing Harrow investor relations.